window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Women in Pharma

Women in PharmaDebbie2026-02-23T12:09:55+00:00
  • Biomanufacturing,CDMOs & Manufacturing,Drug Development,Manufacturing,Pharmaceuticals and therapeutics,Supply Chain & Logistics

    Pharma firms localise GLP-1 supply chains as shortages and geopolitical risks grow

    Drugmakers are regionalising GLP-1 manufacturing as demand surges, shortages persist [...]

    read more
  • Clinical Development,Drug Development,FDA,Neurosciences,Pharmaceuticals and therapeutics,Rare Diseases

    Emalex wins US patent for ecopipam ODT as Tourette access program grows

    Emalex has secured a US patent for an orally disintegrating [...]

    read more
  • Biotech,Drug discovery,Facilities and infrastructure,Research & Development,Technology and platforms

    FairJourney Bio opens cryo-EM facility in San Diego for antibody discovery

    FairJourney Bio has opened a cryo-EM structural biology facility in [...]

    read more
  • Neurosciences,Research & Development

    Kinesin-2 motor variants shown to control cargo transport in neurons

    Researchers in Japan have identified distinct kinesin-2 motor protein assemblies [...]

    read more
  • Central Nervous System,Clinical Development,Drug Delivery & Formulation,Drug Development,Neurosciences,Patient Centricity

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    read more
  • Obesity,Pharmaceuticals and therapeutics,Research & Development

    Currax highlights peer-reviewed review supporting combination approaches in obesity treatment

    Currax Pharmaceuticals is highlighting a peer-reviewed publication supporting the use [...]

    read more
  • Clinical Development,Clinical studies,Hematology,Regulatory Affairs,Research & Development

    MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD

    MaaT Pharma has published retrospective real-world data from its CHRONOS [...]

    read more
  • CDMOs & Manufacturing,Facilities and infrastructure,Manufacturing,Pharmaceuticals and therapeutics

    Symbiosis expands QC capabilities with new 30°C stability chamber

    Symbiosis Pharmaceutical Services has expanded its quality control laboratory in [...]

    read more
  • Clinical Trials,Immunology,Oncology,Research & Development

    Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed

    Kainova Therapeutics has dosed the first European patient in its [...]

    read more
  • Artificial Intelligence,Drug discovery,Research & Development,Technology and platforms

    Chemify founder publishes three papers on programmable chemistry and automated drug discovery

    Chemify founder Lee Cronin has published three peer-reviewed papers outlining [...]

    read more
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Clinical Development, Clinical Trials, Digital Health, Funding, Mental health, Neurosciences, Pharmaceuticals and therapeutics
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical Trials, Oncology
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Clinical Development, Clinical Trials, Healthcare leadership, Oncology
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top